Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23777371 | 0.92 | LMNA (0.40) | CA1CA2ELANEMAPTL3MBTL1 | |
| SCHEMBL18875837 | 0.88 | TGM2 (0.39) | TACR1TGM2KLK7KLK5HTT | |
| SCHEMBL17283437 | 0.86 | MAPK1 (0.42) | TACR1TGM2KLK7KLK5HTT | |
| SCHEMBL18875834 | 0.85 | TGM2 (0.40) | CA1CA2TACR1TGM2KLK7 | |
| SCHEMBL18875836 | 0.85 | TGM2 (0.40) | TACR1TGM2KLK7KLK5HTT | |
| SCHEMBL18875849 | 0.82 | TGM2 (0.42) | TACR1TGM2KLK7KLK5HTT | |
| SCHEMBL18875829 | 0.82 | TGM2 (0.43) | TACR1TGM2KLK7KLK5HTT | |
| SCHEMBL17283436 | 0.82 | KEAP1 (0.40) | TACR1TGM2KLK7KLK5HTT | |
| SCHEMBL24294564 | 0.77 | LMNA (0.47) | HTTMAPTL3MBTL1 | |
| SCHEMBL26813921 | 0.76 | TGM2 (0.53) | CA1CA2MMP2MMP9TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-10570169-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015188194-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015179693-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, FUT6, GALNT13 | CA1 2100/4885CA2 3728/4885TACR1 4399/4885 |
| US-10570169-B2 | Conjugated antisense compounds and their use | GNE, GALNT1, GALNT6 | CA1 1774/4885CA2 3637/4885TACR1 4361/4885 |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | CA1 866/4885CA2 2392/4885TACR1 3018/4885 |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | CA1 866/4885CA2 2392/4885TACR1 3018/4885 |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | CA1 1774/4885CA2 3637/4885TACR1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.